Select a section title of Protocol from following window, and the click "Write Section" button.

2. STUDY OBJECTIVES 2.1 Study Objectives 2.2 Primary Objective 2.3 Secondary Objectives 2.4 Assessment of Objectives 3. BACKGROUND 3.2 Study Agent 3.3 Nonclinical Studies 3.3.1 Animal Toxicology Data 3.3.2 Pharmacologic Profile 3.3.3 Pharmacokinetics 3.3.4 Toxicology 3.2 Study Disease 3.3 Clinical Studies 3.3.1 Phase 1 studies 3.3.2 Phase 2/3 studies 3.3.3 Ketoconazole Interaction Trial 3.3.4 Pharmacokinetics 3.3.5 Safety and Tolerability 3.4 Rationale 4. OVERVIEW OF STUDY DESIGN 4.1 Study design 4.2 Study Design Rationale 4.3 Dosage and Administration 4.5 Sample Size 5. INVESTIGATIONAL PLAN 5.1 PARTICIPANT SELECTION 5.2 Overview of Study Population 5.2.1 Target Population 5.3 Study Population 5.3.1 Patient Population 5.3.2 Inclusion Criteria 5.3.3 Exclusion Criteria 5.3.4 Recruitment and Retention Plan 5.4 Study Period 5.4.1 Dosage and Administration Period 5.4.2 Study Follow-up Period 5.5 Schedule of Study Visits 5.5.1 Screening Period 5.5.2 Baseline Period 5.5.3 Study Treatment Period 5.6 Packaging and labeling 5.7 Treatment assignment and maintenance of the blind 5.7.1 Dose Regimen and Dose Groups 5.7.2 Study Grug Administration 5.7.3 Run-In Procedures 5.7.4 Contraindicationss 5.8 Concomitant Therapies and Medications 5.8.1 Concomitant Therapies 5.8.1 Concomitant Medications 5.9 Patient Compliance 5.9.1 Adherence/Compliance 5.9.2 Dose Modification 5.10 Safety and Laboratory Assessments 5.11 Adverse Events and Serious Adverse Events 5.11.1 Adverse Events 5.11.2 Serious Adverse Event (SAE) 5.11.3 Documentation of Adverse Events 5.12 Steering Committee